ondasdechoque.org
PT-BR

Higher versus lower shockwave energy for trapezius pain · Randomized trial · 2018

Is stronger shockwave better for neck and shoulder muscle pain?

In this small trial, neck and shoulder muscle pain dropped from between 5 and 6 to about 3 out of 10 after two sessions of focused shockwave, one a week, at either a higher or a lower strength. Pain ended about the same in both groups. Neck-related disability scores ended lower with the higher strength.

Both strengths eased pain
adults with recent neck and shoulder muscle pain
30
sessions, one a week
2
weeks of follow-up after the last session
2

Good to know: Small trial (30 people, mostly young women). Everyone had a numbing injection before each session.

Park KD, Lee WY, Park MH, et al. Medicine, 2018 · Read the paper ↗

How this study worked

Higher strength15 peopleLower strength16 people
People were assigned to the groups by lot. Each dot is one person.

Conceptual animation: a focused front converges, then spreads. Not to scale. Tap the field to send a pulse.

What happened

Neck and shoulder muscle pain

0–10 pain scale · start and 2 weeks after the last session

Start2 weeks after treatment

Pain dropped from between 5 and 6 to about 3 out of 10 at both strengths, ending almost the same (3.0 and 3.1).
Show the numbers
GroupPeopleStart2 weeks after treatment
Higher strength155.673
Lower strength155.43.07

The treatment

Higher strength

Focused, once a week for 2 weeks

Focused wavesMeet at a focal zone below the skin
Sessions
2, one a week
Pulses
1,500 per session
Strength
0.210mJ/mm²
Numbing
Local anaesthetic · 5 mL of 1% lidocaine under the skin before every session
Device
Dornier AR2
Everyone also got
Paracetamol if needed, up to 2 g a day

Lower strength

Focused, once a week for 2 weeks

Focused wavesMeet at a focal zone below the skin
Sessions
2, one a week
Pulses
1,500 per session
Strength
0.068mJ/mm²
Numbing
Local anaesthetic · 5 mL of 1% lidocaine under the skin before every session
Device
Dornier AR2
Everyone also got
Paracetamol if needed, up to 2 g a day

Compared with: The same shockwave course at a lower strength

Settings are what each study used, not a prescription.

Who took part

30 adults (27 women; average age about 32) with pain in the muscle across the top of the shoulder and neck that began within the last three months.

hollow squares: no final score

Higher strength15 people
Lower strength15 of 16 measured
30 of 31 people (97%) had a final score.

Side effects

No major side effects were reported, and no one stopped because of side effects. Minor effects were not counted.

All the numbers and the full appraisal

Every reported result

FROM THE FULL PAPER

The results, in numbers.

Upper-trapezius MPS diagnosed with tender taut-band nodule, referred pain and local twitch; pain onset within three months and numeric pain at least 4. Mean age was approximately 32; 27/30 participants were women and mean symptom duration about 8 weeks. This is not a chronic longstanding-pain cohort.

High energy15randomized

15 allocated and analyzed; no follow-up loss in this arm.

Low energy16randomized

16 allocated; one follow-up loss; 15 analyzed.

Verbal numeric scale1 reported outcome
01
Two weeks after last treatment

Pain intensity

Verbal numeric scale Points

BaselineFollow-up
High energy
3
Low energy
3.07
010 Points
Pain intensity · Two weeks after last treatment · means
GroupnBaselineFollow-up
High energy155.67 (SD 1.63)3 (SD 1.56)
Low energy155.4 (SD 1.64)3.07 (SD 1.49)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

REPORTED COMPARISON TESTp = 0.838

High versus low energy endpoint

Mann–Whitney U

No significant between-group difference.

Analysis details and source

Means and SD as reported; endpoint test unadjusted for baseline, no effect CI reported.

Neck Disability Index1 reported outcome
02
Two weeks after last treatment

Neck disability

Neck Disability Index Points

BaselineFollow-up
High energy
4.2
Low energy
6.47
050 Points
Neck disability · Two weeks after last treatment · means
GroupnBaselineFollow-up
High energy1511.27 (SD 4.04)4.2 (SD 1.78)
Low energy159.2 (SD 3.75)6.47 (SD 2.48)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

REPORTED COMPARISON TESTp = 0.008

High versus low energy endpoint

Mann–Whitney U

Higher energy favored.

Analysis details and source

Means and SD as reported; endpoint test unadjusted for baseline, no effect CI reported.

Inclinometer6 reported outcomes
03
Two weeks after last treatment

Neck flexion

Inclinometer Degrees

Neck flexion · Two weeks after last treatment · means
GroupnBaselineFollow-up
High energy1556.53 (SD 14.49)65.47 (SD 10.09)
Low energy1553.8 (SD 10.56)55.93 (SD 11.07)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

REPORTED COMPARISON TESTp = 0.029

High versus low energy endpoint

Mann–Whitney U

Higher energy favored.

Analysis details and source

Means and SD as reported; endpoint test unadjusted for baseline, no effect CI reported.

04
Two weeks after last treatment

Neck extension

Inclinometer Degrees

Neck extension · Two weeks after last treatment · means
GroupnBaselineFollow-up
High energy1561.67 (SD 12.84)68.93 (SD 11.47)
Low energy1567.93 (SD 13.46)72.2 (SD 13.88)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

REPORTED COMPARISON TESTp = 0.486

High versus low energy endpoint

Mann–Whitney U

No significant between-group difference.

Analysis details and source

Means and SD as reported; endpoint test unadjusted for baseline, no effect CI reported.

05
Two weeks after last treatment

Rotation to affected side

Inclinometer Degrees

Rotation to affected side · Two weeks after last treatment · means
GroupnBaselineFollow-up
High energy1569.87 (SD 10.59)74.2 (SD 10.38)
Low energy1571 (SD 10.64)74.4 (SD 8.79)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

REPORTED COMPARISON TESTp = 0.967

High versus low energy endpoint

Mann–Whitney U

No significant between-group difference.

Analysis details and source

Means and SD as reported; endpoint test unadjusted for baseline, no effect CI reported.

06
Two weeks after last treatment

Rotation to unaffected side

Inclinometer Degrees

Rotation to unaffected side · Two weeks after last treatment · means
GroupnBaselineFollow-up
High energy1561.27 (SD 14.42)73 (SD 10.48)
Low energy1562.33 (SD 13.75)71 (SD 11.67)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

REPORTED COMPARISON TESTp = 0.653

High versus low energy endpoint

Mann–Whitney U

No significant between-group difference.

Analysis details and source

Means and SD as reported; endpoint test unadjusted for baseline, no effect CI reported.

07
Two weeks after last treatment

Bending to affected side

Inclinometer Degrees

Bending to affected side · Two weeks after last treatment · means
GroupnBaselineFollow-up
High energy1546.4 (SD 7.52)55.13 (SD 9.72)
Low energy1549.07 (SD 7.33)55.33 (SD 9.81)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

REPORTED COMPARISON TESTp = 0.567

High versus low energy endpoint

Mann–Whitney U

No significant between-group difference.

Analysis details and source

Means and SD as reported; endpoint test unadjusted for baseline, no effect CI reported.

08
Two weeks after last treatment

Bending to unaffected side

Inclinometer Degrees

Bending to unaffected side · Two weeks after last treatment · means
GroupnBaselineFollow-up
High energy1541.4 (SD 8.82)54.27 (SD 10.81)
Low energy1539.87 (SD 7.41)48.13 (SD 8.83)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

REPORTED COMPARISON TESTp = 0.137

High versus low energy endpoint

Mann–Whitney U

No significant between-group difference.

Analysis details and source

Means and SD as reported; endpoint test unadjusted for baseline, no effect CI reported.

Algometer1 reported outcome
09
Two weeks after last treatment

Pressure pain threshold

Algometer kg/cm²

Pressure pain threshold · Two weeks after last treatment · means
GroupnBaselineFollow-up
High energy151.63 (SD 0.37)2.32 (SD 0.55)
Low energy151.67 (SD 0.49)2.05 (SD 0.55)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

REPORTED COMPARISON TESTp = 0.217

High versus low energy endpoint

Mann–Whitney U

No significant between-group difference.

Analysis details and source

Means and SD as reported; endpoint test unadjusted for baseline, no effect CI reported.

How treatment was delivered
High-energy regimen

Dornier AR2 focused treatment to the upper-trapezius trigger point (the more painful side when both sides were affected): 1,500 pulses once weekly for two weeks, 0.210 mJ/mm² in the high-energy arm. All patients received 5 mL of 1% subcutaneous lidocaine before every session. Pulse frequency was not reported.

Low-energy and shared care

Lower-energy arm used 0.068 mJ/mm² with the same pulses, sessions and local anesthesia. Rescue acetaminophen up to 2 g/day was allowed; other conservative treatments were prohibited until follow-up. No sham group was included.

HARMS & TOLERABILITY

No major adverse effects or withdrawals due to side effects were reported; minor-event frequency was not tabulated. A Korean health-research grant is acknowledged, despite an inconsistent no-funding sentence in the front matter. Authors declared no commercial benefits or conflicts.

LIMITS OF THE ANALYSIS

Only 15 analyzed per arm, predominantly young women, short follow-up and no sham limit generalization. NDI baseline differed numerically and comparisons used unadjusted endpoints. Multiple outcomes raise false-positive concerns. Equal lidocaine exposure may modify the shockwave response and cannot establish results without anesthesia. Figure 1 shows 31 randomized (15 high, 16 low), with one low-energy follow-up loss and 30 analyzed. Its final labels claiming 15 excluded from analysis in each arm contradict the analyzed counts and appear to be diagram errors.

Findings checked against the full source by a separate automated reviewer.

Limitations noted by the reviewers

  • Only 15 analyzed per arm, predominantly young women, short follow-up and no sham limit generalization. NDI baseline differed numerically and comparisons used unadjusted endpoints. Multiple outcomes raise false-positive concerns. Equal lidocaine exposure may modify the shockwave response and cannot establish results without anesthesia. Figure 1 shows 31 randomized (15 high, 16 low), with one low-energy follow-up loss and 30 analyzed. Its final labels claiming 15 excluded from analysis in each arm contradict the analyzed counts and appear to be diagram errors.
Research review

Source-linked critical reading

Randomized pilot trial with random-number block allocation and opaque envelopes; patients and follow-up assessors were blinded. Thirty participants were analyzed. The flow describes 37 assessed, six declining after symptom relief and one follow-up loss.

Reading depthMaterial consulted
Technical source record

Full local PDF read; All 7 PDF pages; Methods; Results; Tables 1–3; Figure 1; Discussion including anesthesia limitation and pain-conclusion discrepancy; Funding; conflicts; references

Review statusAI-assisted draft · independent automated checkThis automated check comes before the editor’s clinical review.
Study design

Randomized pilot trial with random-number block allocation and opaque envelopes; patients and follow-up assessors were blinded. Thirty participants were analyzed. The flow describes 37 assessed, six declining after symptom relief and one follow-up loss. Figure 1 shows 31 randomized (15 high, 16 low), with one low-energy follow-up loss and 30 analyzed. Its final labels claiming 15 excluded from analysis in each arm contradict the analyzed counts and appear to be diagram errors.

Participants and setting

Upper-trapezius MPS diagnosed with tender taut-band nodule, referred pain and local twitch; pain onset within three months and numeric pain at least 4. Mean age was approximately 32; 27/30 participants were women and mean symptom duration about 8 weeks. This is not a chronic longstanding-pain cohort.

Treatment protocol

Dornier AR2 focused treatment to the upper-trapezius trigger point (the more painful side when both sides were affected): 1,500 pulses once weekly for two weeks, 0.210 mJ/mm² in the high-energy arm. All patients received 5 mL of 1% subcutaneous lidocaine before every session. Pulse frequency was not reported.

Comparison

Lower-energy arm used 0.068 mJ/mm² with the same pulses, sessions and local anesthesia. Rescue acetaminophen up to 2 g/day was allowed; other conservative treatments were prohibited until follow-up. No sham group was included.

What was measured

Verbal numeric pain 0–10, NDI 0–50, pressure pain threshold in kg/cm² and six cervical range-of-motion directions were assessed before and two weeks after the last treatment. Tables 2–3 distinguish paired improvement from endpoint comparisons.

Results and interpretation

At follow-up pain was 3.00 versus 3.07 (p=.838), showing no higher-energy advantage. NDI was 4.20 versus 6.47 (p=.008), and flexion 65.47° versus 55.93° (p=.029), favoring higher energy. Pressure threshold and other movement directions did not differ significantly. The conclusion wording claiming superior pain relief overstates the actual between-group pain test.

Harms and disclosures

No major adverse effects or withdrawals due to side effects were reported; minor-event frequency was not tabulated. A Korean health-research grant is acknowledged, despite an inconsistent no-funding sentence in the front matter. Authors declared no commercial benefits or conflicts.

Limitations

Only 15 analyzed per arm, predominantly young women, short follow-up and no sham limit generalization. NDI baseline differed numerically and comparisons used unadjusted endpoints. Multiple outcomes raise false-positive concerns. Equal lidocaine exposure may modify the shockwave response and cannot establish results without anesthesia.

Applicability

Findings concern two short-course focused regimens under local anesthesia in relatively recent MPS. They do not establish that more energy is universally better or that observed disability differences are durable.

What stronger evidence needs

A larger prespecified dose trial should adjust baseline outcomes, include a credible sham, report analgesic use and minor harms, and follow function for months with and without local anesthesia.

THE ORIGINAL SOURCE

Read the original article.

High- versus low-energy extracorporeal shock-wave therapy for myofascial pain syndrome of upper trapezius: A prospective randomized single blinded pilot study.

Park KD, Lee WY, Park MH, Ahn JK, Park Y. · Medicine · 2018

Open the publication record or available full-text files.

Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →